ENDO-AID Assisted Tandem Colonoscopy RCT
Launched by CHINESE UNIVERSITY OF HONG KONG · Aug 13, 2021
Trial Information
Current as of May 19, 2025
Completed
Keywords
ClinConnect Summary
Colorectal cancer is the third common cancer in the world and the commonest cancer in Hong Kong. Most sporadic colorectal cancers arise from benign polyps via adenoma-carcinoma sequence or the serrated polyp-carcinoma sequence. There are reports of unexpectedly high risk of interval carcinomas, as high as up to 9%, raising concerns about the effectiveness of colonoscopy in preventing colorectal cancers. Different techniques have been described to improve the area of mucosa visualised but lesions may still be missed due to failure of identification by the endoscopist.
Computer Aided diagnos...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients aged 18years or above
- • Referred to endoscopy unit for diagnostic or surveillance colonoscopy
- Exclusion Criteria:
- • Familial history of Familial adenomatous polyposis / Hereditary non-polyposis colorectal cancer
- • Known history of inflammatory bowel disease
- • Known colitis or suspicion of colitis (inflammatory bowel disease, diverticulitis, infective colitis)
- • Emergency endoscopy of any nature (eg gastrointestinal bleeding, colonic decompression)
- • Previous incomplete colonoscopy (not including insufficient preparation) / difficult colonoscopy
- • Patients referred for a therapeutic procedure or assessment of a known non-resected lesion
- • Patients with known palliative colorectal malignancy
- • Patient with coagulopathy
- • Patient with colostomy
- • Patient with multiple co-morbidities (American Society of Anaesthesiologist \>3)
- • Inability to give informed consent
About Chinese University Of Hong Kong
The Chinese University of Hong Kong (CUHK) is a prestigious research institution renowned for its commitment to advancing medical science and improving healthcare outcomes. As a clinical trial sponsor, CUHK leverages its extensive academic resources and interdisciplinary expertise to conduct innovative research that addresses critical health challenges. The university fosters collaboration among leading researchers, healthcare professionals, and industry partners, ensuring rigorous study design and implementation. CUHK is dedicated to upholding the highest ethical standards in clinical research, with a focus on translating findings into tangible benefits for patients and the broader community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Shatin, New Territories, Hong Kong
Patients applied
Trial Officials
Kaori Futaba
Principal Investigator
Chinese University of Hong Kong
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials